Top Dx Financial Planning Mistakes You Must Avoid | Diaceutics

Top Dx Financial Planning Mistakes You Must Avoid

May 24th, 2016

Top Dx Financial Planning Mistakes You Must Avoid

When it comes to financial planning in the pharmaceutical industry there are five common mistakes that must absolutely be avoided. To understand how to remedy these mistakes, it helps to realize that one is an overarching problem in pharma financial planning, and the other four are contributing problems to this. They are:

  1. Failing to carefully vary the annual strategy and budget each year
  2. Neglecting to select specific goals
  3. Using weak or using no analytics
  4. A lack of discipline in allocating budgets
  5. Failure to allocate sufficient budget for Dx strategy implementation

Failure to implement systems to enforce accountability and timeliness

The first item is the overarching problem. By attending to items 2 through 5 you will go far toward remedying the problem of sticking to stagnant financial strategies. It’s important to have a flexible and responsive method of creating your annual financial plan because there are many changes to the industry that will affect you each year. Health fads, environmental hazards and responses to them, and people’s behaviors are all subject to change. Further, new research may emerge affecting the medication prescribed by the physician. These are just a few of the reasons that you must take a careful look at your annual budget and resist the temptation to recycle the same plan year after year.

Goal Specificity

Hopefully, earnings goals can reasonably be aimed higher this year than last year. It will be necessary to take a close look at the market and discover where trends are leading, who is investing in what, and what innovations the research community has delivered. A degree of prescience may be required, but if you know the market, you’ll have it.

Key Analytics

Guessing is off the table. There is a host of analytic tools available for use today- and there are many services out there who specialize in pharmaceutical market analytics. It’s been said by specialists that there is no such thing as perfect guidance. But when your team is shooting in the dark, some guidance is better than none.

Accountability and Timeliness Systems

Assign specific tasks to specific team members with guidance according to actions and time constraints. Every complex project can be simplified by breaking it down and handling it in bits. So, it is wise to assign different parts of the financial plan to different members of your team. This will help to reevaluate accountability and scheduling in reviews.

Whether it’s fear or a lack of imagination that keep so many organizations from breaking away from previous financial plans, the truth is that the problem has reached epidemic proportions. That’s good news for those who manage to break the spell, as they will easily stand out from the rest- but bad news for those who fail to break away from worn out and overused financial planning patterns.

Diaceutics CTA FP

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications